化疗短缺对美国晚期癌症患者的现实影响
Jacob B Reibel1, Lova L Sun1, Ravi B Parikh1,2
1Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.
化疗短缺导致其使用减少了2.7%,在2023年6月达到15.1%的峰值下降. 在短缺期间没有观察到显著的短期死亡率差异.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 全国范围内的基于的化疗药物 (cisplatin和carboplatin) 短缺于2023年2月开始.
- 这种短缺对美国各地的癌症患者护理构成了重大挑战.
研究的目的:
- 量化化疗短缺对处方模式的影响.
- 评估成人癌症患者缺乏和短期死亡率之间的关联.
主要方法:
- 一项队列研究分析了11,797名患有先进固体癌症的成年人进行一线治疗.
- 数据比较是在短缺之前的一年 (2022年2月至2023年2月) 和短缺期间 (2023年2月至2024年1月) 的数据.
- 评估了处方率和短期死亡率,随访时间中位数为7.6个月.
主要成果:
- 在短缺期间,与前一年相比,化疗使用的绝对减少2.7%.
- 在2023年6月的高峰期,与2022年6月相比,的处方减少了15.1%.
- 在短暂死亡率中,在短缺期和短缺期之间没有发现统计学上显著的差异 (aHR 1.00,95% CI 0.94-1.07).
结论:
- 化疗短缺导致药物利用率略有下降.
- 短期死亡率似乎没有受到这种患者队列短缺的显著影响.
- 需要进一步的研究,以了解短缺对癌症患者结果的长期影响.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
相关概念视频
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
